Equity Profile

NKTR

Nektar Therapeutics

Health CarePharmaceuticals$1.9B

Nov8Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EST

Company Snapshot

Nektar Therapeutics is a pharmaceutical company focused on developing innovative therapies for cancer and autoimmune diseases. With a market cap of $2 billion, it operates in the health care sector, which is increasingly important as demand for advanced medical treatments continues to grow.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

NKTR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-162.69%

Avg Stock Reaction

-0.53%

Last Quarter Recap

In Q1-2026, Nektar reported an EPS of -$1.82, which was slightly worse than the expected -$1.74, resulting in a 2.02% drop in stock price the following day. The company continues to face challenges in meeting revenue expectations.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Nektar's upcoming earnings report, hoping for signs of improved financial performance despite recent misses. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Nektar can show a significant reduction in losses or even a surprise positive EPS, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company reports larger-than-expected losses or fails to provide any positive updates, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

The EPS figure will be crucial in determining whether the company is making progress in reducing losses, which investors are eager to see.

What updates can management provide on revenue growth initiatives?

Any insights into revenue growth strategies will help investors gauge the company's potential for future profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Nektar's potential for a turnaround, as recent developments in their pipeline could lead to unexpected revenue streams.

Supporting Evidence

The options market is pricing a larger move than historical averages, indicating potential for volatility.

Nektar's recent pipeline advancements may not be fully reflected in current analyst expectations.

Key Risk

If the company can demonstrate a clear path to reducing losses or achieving revenue growth, it could challenge current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for Nektar as it continues to seek a path toward profitability amid a challenging market environment.

Bull Confirmed If

A reduction in EPS losses to below -$1.50 would indicate improving financial health.

Bear Confirmed If

An EPS loss greater than -$2.00 would confirm ongoing struggles and likely lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±11.48%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±11.5% while NKTR has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

62.9%

Calls (67K)P/C Ratio: 1.63Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nektar beats expectations and raises guidance, history suggests a potential stock increase of around 1.58% on the following day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted reactions, reflecting investor caution.

Miss

A significant miss could lead to a decline, with historical patterns suggesting an average drop of around 0.10% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trial results.
2Management's commentary on cost-cutting measures and their impact on EPS.
3Insights into partnerships or collaborations that could enhance revenue.
4Details on market expansion strategies and their expected outcomes.
5Any guidance on future earnings expectations or financial targets.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

EOG Resources, Inc.

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, crucial for long-term success.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

NKTR Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-162.69%

Avg Stock Reaction

-0.53%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Nektar can show a significant reduction in losses or even a surprise positive EPS, it could signal a turnaround and boost investor confidence.

Bear Case

Conversely, if the company reports larger-than-expected losses or fails to provide any positive updates, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

The EPS figure will be crucial in determining whether the company is making progress in reducing losses, which investors are eager to see.

What updates can management provide on revenue growth initiatives?

Any insights into revenue growth strategies will help investors gauge the company's potential for future profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Nektar's potential for a turnaround, as recent developments in their pipeline could lead to unexpected revenue streams.

Supporting Evidence

The options market is pricing a larger move than historical averages, indicating potential for volatility.

Nektar's recent pipeline advancements may not be fully reflected in current analyst expectations.

Key Risk

If the company can demonstrate a clear path to reducing losses or achieving revenue growth, it could challenge current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for Nektar as it continues to seek a path toward profitability amid a challenging market environment.

Bull Confirmed If

A reduction in EPS losses to below -$1.50 would indicate improving financial health.

Bear Confirmed If

An EPS loss greater than -$2.00 would confirm ongoing struggles and likely lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±11.48%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±11.5% while NKTR has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

62.9%

Calls (67K)P/C Ratio: 1.63Puts (7K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Nektar beats expectations and raises guidance, history suggests a potential stock increase of around 1.58% on the following day.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted reactions, reflecting investor caution.

Miss

A significant miss could lead to a decline, with historical patterns suggesting an average drop of around 0.10% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or clinical trial results.
2Management's commentary on cost-cutting measures and their impact on EPS.
3Insights into partnerships or collaborations that could enhance revenue.
4Details on market expansion strategies and their expected outcomes.
5Any guidance on future earnings expectations or financial targets.